Cristiana Sieiro Santos: EULAR 2025 Recommendations for Systemic Lupus Erythematosus with Kidney Involvement
Cristiana Sieiro Santos, Postdoctoral Research Fellow at The University of Manchester, shared a post on LinkedIn about a paper by Antonis Fanouriakis et al. published in Annals of the Rheumatic Diseases:
“EULAR 2025 Recommendations for Systemic Lupus Erythematosus (SLE) with Kidney Involvement
A major update published in Annals of the Rheumatic Diseases (Fanouriakis et al., 2025) provides evidence-based and consensus-driven guidance for managing lupus nephritis, reflecting recent advances and new therapeutic options.
Key highlights
- Diagnosis and monitoring – Kidney biopsy remains essential. Aim for preserved/improved kidney function at 3 months, and proteinuria <700 mg/g at 12 months.
- Combination therapy – Early use of glucocorticoids (rapid taper), mycophenolate or low-dose IV cyclophosphamide combined with biologics (belimumab, obinutuzumab) or calcineurin inhibitors (voclosporin, tacrolimus).
- Steroid minimisation– ≤5 mg/day by 4–6 months, with the goal of withdrawal once sustained response is achieved.
- Non-immune management– Incorporates RAAS blockade, SGLT2 inhibitors, cardiovascular and bone protection, and up-to-date vaccination strategies.
- Multidisciplinary care– Shared rheumatology–nephrology management and informed decision-making are central to improving long-term outcomes.
Pregnancy should be planned only after ≥6 months of inactive nephritis, with compatible medications and close multidisciplinary supervision.
Kidney replacement therapies, including pre-emptive transplantation, are recommended once extrarenal disease is controlled.”
Title: EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update
Authors: Antonis Fanouriakis, Myrto Kostopoulou, Hans-Joachim Anders, Jeanette Andersen, Martin Aringer, Michael W. Beresford, Andrea Doria, Eleni Frangou, Richard Furie, Dafna D. Gladman, Frederic Houssiau, Alexandre Karras, Marios Kouloumas, Anastasia-Vasiliki Madenidou, Ana Malvar, Smaragdi Marinaki, Chi Chiu Mok, Gabriella Moroni, Ioannis Parodis, Simona Rednic, Cristiana Sieiro Santos, Carlo Alberto Scire, Josef S. Smolen, Farah Tamirou, Yoshiya Tanaka, Y. K. Onno Teng, Elisabet Welin, George Bertsias, Dimitrios T. Boumpas
Read the full article.
-
Oct 11, 2025, 06:44The Global IVF Market Is Set to Reach $65B by 2032 – Meddilink
-
Jan 11, 2026, 10:02Hind Hanani: Understanding the Use of Antiphospholipid Syndrome Guidelines Worldwide
-
Jan 11, 2026, 09:58Exploring the Role of Antiphospholipid Antibodies in Severe Preeclampsia – RheumNow
-
Jan 11, 2026, 09:56Adrenal Involvement in Antiphospholipid Syndrome – ARP Rheumatology
-
Jan 11, 2026, 09:52Jamie Agunsday: Understanding Pregnancy-Related Deaths
-
Jan 11, 2026, 09:48Heghine Khachatryan: Rethinking First-Line Therapy for Iron Deficiency Anemia in Women
-
Jan 11, 2026, 09:44AdhesioRT Test Models Endometrial Receptivity to Optimize Implantation Timing – RBMO
-
Jan 11, 2026, 09:21ACOG Announces Maternal Health Awareness Day 2026 Webinar
-
Jan 11, 2026, 06:59John Cush: Subcutaneous Anifrolumab Effective in Lupus
-
Jan 10, 2026, 06:50Owen Xian Wen Tan: New Insights on β2-Glycoprotein I in Thrombosis Regulation